These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 18446478)
1. Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note. Khan S; Ali A; Singhavi D; Yeole P AAPS PharmSciTech; 2008; 9(1):169-73. PubMed ID: 18446478 [No Abstract] [Full Text] [Related]
2. Eudragit microparticles as a possible tool for ophthalmic administration of acyclovir. Cortesi R; Ajanji SC; Sivieri E; Manservigi M; Fundueanu G; Menegatti E; Esposito E J Microencapsul; 2007 Aug; 24(5):445-56. PubMed ID: 17578734 [TBL] [Abstract][Full Text] [Related]
3. Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye? Pijls RT; Hanssen HH; Nuijts RM; Koole LH Biomed Mater Eng; 2004; 14(4):383-93. PubMed ID: 15472387 [TBL] [Abstract][Full Text] [Related]
4. Floating properties and release characteristics of hollow microspheres of acyclovir. Junyaprasert VB; Pornsuwannapha S Drug Deliv; 2008 Jun; 15(5):331-41. PubMed ID: 18763164 [TBL] [Abstract][Full Text] [Related]
7. In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery. Gandhi A; Jana S; Sen KK Int J Biol Macromol; 2014 Jun; 67():478-82. PubMed ID: 24755259 [TBL] [Abstract][Full Text] [Related]
10. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. Xu X; Al-Ghabeish M; Rahman Z; Krishnaiah YS; Yerlikaya F; Yang Y; Manda P; Hunt RL; Khan MA Int J Pharm; 2015 Sep; 493(1-2):412-25. PubMed ID: 26231106 [TBL] [Abstract][Full Text] [Related]
11. Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery. Baskakova A; Awwad S; Jiménez JQ; Gill H; Novikov O; Khaw PT; Brocchini S; Zhilyakova E; Williams GR Int J Pharm; 2016 Apr; 502(1-2):208-18. PubMed ID: 26899973 [TBL] [Abstract][Full Text] [Related]
12. Development and characterization of sponge-like acyclovir ocular minitablets. Refai H; Tag R Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440 [TBL] [Abstract][Full Text] [Related]
13. A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies. Rathod LV; Kapadia R; Sawant KK Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():529-540. PubMed ID: 27987741 [TBL] [Abstract][Full Text] [Related]
15. Topical delivery of acyclovir and ketoconazole. Jacobs GA; Gerber M; Malan MM; du Preez JL; Fox LT; du Plessis J Drug Deliv; 2016; 23(2):631-41. PubMed ID: 25005585 [TBL] [Abstract][Full Text] [Related]
16. Soluplus micelles for acyclovir ocular delivery: Formulation and cornea and sclera permeability. Varela-Garcia A; Concheiro A; Alvarez-Lorenzo C Int J Pharm; 2018 Dec; 552(1-2):39-47. PubMed ID: 30253214 [TBL] [Abstract][Full Text] [Related]
18. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. Aburahma MH; Mahmoud AA AAPS PharmSciTech; 2011 Dec; 12(4):1335-47. PubMed ID: 21979886 [TBL] [Abstract][Full Text] [Related]
19. The role of lipid-based drug delivery systems for enhancing solubility of highly selective antiviral agent acyclovir. Kazi M; Al-Amri KA; Alanazi FK Pharm Dev Technol; 2017 May; 22(3):312-321. PubMed ID: 26458371 [TBL] [Abstract][Full Text] [Related]
20. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Das S; Suresh PK; Desmukh R Nanomedicine; 2010 Apr; 6(2):318-23. PubMed ID: 19800990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]